Can a new pill outsmart resistant breast cancer?

NCT ID NCT07766018

Recruiting now Disease control Sponsor: Stemline Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This trial is testing an oral drug called elacestrant in Japanese patients with a specific type of advanced breast cancer (ER+/HER2-) that has a mutation in the ESR1 gene and has progressed after prior endocrine therapy including a CDK4/6 inhibitor. The study aims to see if elacestrant can slow down the cancer's growth and to assess its safety. Participants will take elacestrant as a tablet, and the trial will monitor their response and any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: elacestrant (an oral drug taken as a tablet)
What this could lead to: If successful, this could provide a new treatment option for Japanese patients with a specific type of advanced breast cancer that has stopped responding to prior therapies.
What could go wrong: This is a phase 2 trial with a small number of participants, so results may not be conclusive. The drug may not be effective or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ER+/HER2- ADVANCED OR METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ER+/HER2- ADVANCED OR METASTATIC BREAST CANCER

Contacts and locations

Locations

Tokai University Hospital
RECRUITING

Isehara, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.